Adenylate Kinase and Metabolic Signaling in Cancer Cells.
adenylate kinase
cancer
energy metabolism
mitochondria
phosphotransfer
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2020
2020
Historique:
received:
15
02
2020
accepted:
08
04
2020
entrez:
9
6
2020
pubmed:
9
6
2020
medline:
9
6
2020
Statut:
epublish
Résumé
A hallmark of cancer cells is the ability to rewire their bioenergetics and metabolic signaling circuits to fuel their uncontrolled proliferation and metastasis. Adenylate kinase (AK) is the critical enzyme in the metabolic monitoring of cellular adenine nucleotide homeostasis. It also directs AK→ AMP→ AMPK signaling controlling cell cycle and proliferation, and ATP energy transfer from mitochondria to distribute energy among cellular processes. The significance of AK isoform network in the regulation of a variety of cellular processes, which include cell differentiation and motility, is rapidly growing. Adenylate kinase 2 (AK2) isoform, localized in intermembrane and intra-cristae space, is vital for mitochondria nucleotide exchange and ATP export. AK2 deficiency disrupts cell energetics, causes severe human diseases, and is embryonically lethal in mice, signifying the importance of catalyzed phosphotransfer in cellular energetics. Suppression of AK phosphotransfer and AMP generation in cancer cells and consequently signaling through AMPK could be an important factor in the initiation of cancerous transformation, unleashing uncontrolled cell cycle and growth. Evidence also builds up that shift in AK isoforms is used later by cancer cells for rewiring energy metabolism to support their high proliferation activity and tumor progression. As cell motility is an energy-consuming process, positioning of AK isoforms to increased energy consumption sites could be an essential factor to incline cancer cells to metastases. In this review, we summarize recent advances in studies of the significance of AK isoforms involved in cancer cell metabolism, metabolic signaling, metastatic potential, and a therapeutic target.
Identifiants
pubmed: 32509571
doi: 10.3389/fonc.2020.00660
pmc: PMC7248387
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
660Informations de copyright
Copyright © 2020 Klepinin, Zhang, Klepinina, Rebane-Klemm, Terzic, Kaambre and Dzeja.
Références
Biochem Biophys Rep. 2015 Aug 29;4:111-125
pubmed: 29124194
Comp Biochem Physiol B Biochem Mol Biol. 2009 May;153(1):29-38
pubmed: 19416704
Int J Biochem Cell Biol. 2013 May;45(5):979-86
pubmed: 23416112
Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6152-8
pubmed: 15448002
J Cell Biochem. 2011 Apr;112(4):1066-75
pubmed: 21308735
Nat Commun. 2014;5:3351
pubmed: 24548998
Front Pharmacol. 2012 Nov 07;3:192
pubmed: 23162466
Nat Commun. 2017 May 18;8:15308
pubmed: 28516914
Clin Cancer Res. 2009 Oct 15;15(20):6327-40
pubmed: 19808870
Oncotarget. 2015 Oct 13;6(31):30453-71
pubmed: 26421711
Biochim Biophys Acta Gen Subj. 2017 Aug;1861(8):2146-2154
pubmed: 28552560
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Sci Rep. 2019 Aug 23;9(1):12329
pubmed: 31444368
Mol Cell. 2007 Mar 9;25(5):647-61
pubmed: 17349953
Semin Cancer Biol. 2007 Jun;17(3):241-7
pubmed: 16839774
Biochem Biophys Res Commun. 2018 Mar 4;497(2):719-725
pubmed: 29462620
Mech Ageing Dev. 1991 Nov 15;61(1):11-22
pubmed: 1779698
Cancer Res. 2008 Jun 1;68(11):4018-21
pubmed: 18519656
PLoS One. 2011 Apr 27;6(4):e19300
pubmed: 21556322
BMC Cancer. 2018 Jun 4;18(1):631
pubmed: 29866054
J Biol Chem. 1996 Jul 12;271(28):16544-52
pubmed: 8663240
Biochim Biophys Acta. 2010 Jun-Jul;1797(6-7):1018-27
pubmed: 20144582
J Hematol Oncol. 2019 Jan 29;12(1):12
pubmed: 30696468
Nat Commun. 2016 Aug 01;7:12310
pubmed: 27477389
Mol Cancer. 2005 Jan 16;4(1):4
pubmed: 15651998
Int J Mol Sci. 2009 Apr 17;10(4):1729-72
pubmed: 19468337
Mol Carcinog. 2019 Nov;58(11):2161-2174
pubmed: 31486135
FASEB J. 2012 Jun;26(6):2685-94
pubmed: 22415305
BMC Biol. 2013 Apr 15;11:36
pubmed: 23587167
Biochim Biophys Acta. 1985 Aug 16;841(2):195-200
pubmed: 2990572
FEBS J. 2008 Jun;275(12):3236-47
pubmed: 18485002
Cancer Res. 1984 Mar;44(3):1058-62
pubmed: 6692392
J Immunother Cancer. 2018 Jun 18;6(1):57
pubmed: 29914571
Metabolomics. 2010 Sep;6(3):439-450
pubmed: 20676217
Clin Exp Med. 2019 Nov;19(4):525-534
pubmed: 31463832
Biofactors. 2009 Mar-Apr;35(2):209-25
pubmed: 19449450
Trends Pharmacol Sci. 2016 Mar;37(3):192-206
pubmed: 26711141
Sci Rep. 2019 Oct 31;9(1):15739
pubmed: 31673062
PLoS One. 2010 Feb 05;5(2):e9075
pubmed: 20140087
J Biol Chem. 2007 Oct 26;282(43):31366-72
pubmed: 17704060
Int J Biochem Cell Biol. 2009 Jun;41(6):1371-80
pubmed: 19130895
J Med Invest. 2014;61(1-2):137-50
pubmed: 24705759
J Biol Chem. 2003 Aug 15;278(33):30441-9
pubmed: 12730234
BMC Pulm Med. 2020 Jan 13;20(1):10
pubmed: 31931771
J Exp Biol. 2003 Jun;206(Pt 12):2039-47
pubmed: 12756286
Sci Rep. 2019 Nov 28;9(1):17757
pubmed: 31780678
Biomol Ther (Seoul). 2018 Jan 1;26(1):19-28
pubmed: 29212303
Lab Invest. 2018 Feb;98(2):164-174
pubmed: 29451272
J Biol Chem. 2009 Jan 16;284(3):1620-7
pubmed: 19008233
Pharmacol Ther. 2000 Aug-Sep;87(2-3):189-98
pubmed: 11008000
Mol Cell Biochem. 1998 Jul;184(1-2):169-82
pubmed: 9746320
Nature. 2008 Jan 17;451(7176):345-9
pubmed: 18202660
Nat Rev Cancer. 2009 Aug;9(8):563-75
pubmed: 19629071
J Biol Chem. 2003 Apr 11;278(15):12937-45
pubmed: 12562761
Proc Natl Acad Sci U S A. 2001 Jun 19;98(13):7623-8
pubmed: 11390963
Oncogene. 1999 Oct 21;18(43):5879-88
pubmed: 10557075
Cell Rep. 2014 May 8;7(3):907-17
pubmed: 24767988
J Bioenerg Biomembr. 2018 Oct;50(5):339-354
pubmed: 29998379
Nat Commun. 2019 Sep 18;10(1):4255
pubmed: 31534141
Int J Biochem Cell Biol. 2014 Oct;55:171-86
pubmed: 25218857
Clin Cancer Res. 2004 Jan 15;10(2):708-17
pubmed: 14760094
Int J Clin Exp Pathol. 2018 Jan 01;11(1):216-223
pubmed: 31938103
Nat Commun. 2016 Dec 22;7:13864
pubmed: 28004795
J Physiol. 2011 Nov 1;589(Pt 21):5193-211
pubmed: 21878522
Cell. 1997 Apr 4;89(1):93-103
pubmed: 9094718
J Bioenerg Biomembr. 2012 Oct;44(5):539-58
pubmed: 22836527
FEBS J. 2007 Mar;274(6):1393-418
pubmed: 17302740
Arch Biochem Biophys. 2013 May;533(1-2):11-7
pubmed: 23474458
J Med Invest. 2005 Aug;52(3-4):127-36
pubmed: 16167529
World J Stem Cells. 2015 Mar 26;7(2):418-27
pubmed: 25815125
Nat Cell Biol. 2007 Nov;9(11):1303-10
pubmed: 17952061
Int J Biochem Cell Biol. 2014 Apr;49:75-83
pubmed: 24495878
J Bioenerg Biomembr. 2007 Jun;39(3):211-22
pubmed: 17879147
Mol Cancer. 2016 Nov 8;15(1):69
pubmed: 27825361
Mol Cell Biochem. 2004 Jan-Feb;256-257(1-2):13-27
pubmed: 14977167
Biochim Biophys Acta. 2011 Jun;1807(6):552-61
pubmed: 20955683
FASEB J. 1998 May;12(7):523-9
pubmed: 9576479
J Bioenerg Biomembr. 2016 Oct;48(5):531-548
pubmed: 27854030
Cell Metab. 2020 Mar 3;31(3):472-492
pubmed: 32130880
Cancer Cell Int. 2018 Nov 16;18:186
pubmed: 30479565
Cancer Res. 2009 Jul 1;69(13):5406-14
pubmed: 19491280
Proc Natl Acad Sci U S A. 2002 Jul 23;99(15):10156-61
pubmed: 12119406
Nat Rev Mol Cell Biol. 2007 Oct;8(10):774-85
pubmed: 17712357
J Exp Clin Cancer Res. 2016 Mar 16;35:48
pubmed: 26980435
Nature. 2011 Apr 14;472(7342):230-3
pubmed: 21399626
Biochem Soc Trans. 2011 Jan;39(1):1-13
pubmed: 21265739
Cancer Res. 2012 Oct 1;72(19):5119-29
pubmed: 23002211
J Cancer. 2016 Jan 01;7(1):50-9
pubmed: 26722360
J Mol Cell Cardiol. 2010 Apr;48(4):725-34
pubmed: 20045004
Nat Genet. 2009 Jan;41(1):106-11
pubmed: 19043416
Cell. 1993 Aug 27;74(4):621-31
pubmed: 8358791
Front Oncol. 2020 Mar 02;10:159
pubmed: 32195169
Nat Genet. 2009 Jan;41(1):101-5
pubmed: 19043417
Chem Biol. 2014 Nov 20;21(11):1497-1510
pubmed: 25459662
J Physiol. 2006 Mar 1;571(Pt 2):253-73
pubmed: 16410283
Cancer Res. 1970 Feb;30(2):370-5
pubmed: 4394072
Dis Markers. 2019 Nov 20;2019:8186091
pubmed: 31827645
Int J Oncol. 2003 Aug;23(2):533-9
pubmed: 12851706
J Bioenerg Biomembr. 2014 Feb;46(1):17-31
pubmed: 24072403
Cancer Cell. 2006 Jun;9(6):425-34
pubmed: 16766262